UK & Europe
Clyde & Co has advised OxSyBio Limited, a UK-based 3D bioprinting developer, on a multimillion funding round securing funds from investors including Parkwalk Advisors, owned by the firm IP Group.
OxSyBio, founded in 2014, develops 3D printing techniques to produce a range of tissue-like materials and functional tissues for medical research and clinical applications. So far, OxSyBio has developed a 3D-printing technique capable of producing human cell-like structures and long-term they hope to refine the technology to offer organ repair and replacement capabilities.
Clyde & Co’s team drafted and negotiated all deal documentation and managed multiple parties over the course of the transaction, ensuring that a significant total was raised, split over two completions.
The Clyde & Co team which advised on the deal was led by Partner Simon Gamblin, supported by Christine Brennan and Nick Long.
Dr Hadrian Green, CEO of OxSyBio commented, “Simon Gamblin and the Clyde and Co team’s advice and expertise were key to maintaining the momentum of a transaction that is critical to the next chapter of OxSyBio’s technology platform.
Simon Gamblin says, “We were extremely pleased to assist Hadrian and his team in relation to this financing, which will accelerate OxSyBio's already impressive plans for being able to produce tissues that can be used in the clinic for organ repair or replacement."
The deal is significant for OxSyBio and its niche area of developing 3D printing technology within the life sciences sector. It has enabled significant funds to be raised where previously it had relied on much smaller shareholder loans to sustain its activities for short periods. OxSyBio is now able to invest into, expand and potentially commercialise its technology.
The Clyde & Co corporate and commercial team assist in offering practical business advice to both early stage and more mature companies, enabling them to grow with confidence and make the right strategic decisions. Their deep sector knowledge and experience allows them to provide practical, commercially focused advice, to help clients achieve their ambitions and strategic objectives in a cost-effective way.